Granulosa cell tumor
Also known as: Fibroid, Leiomyoma, Fibrous, Tumor
Methodology & AI Transparency ⓘ
Granulosa cell tumor Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Granulosa cell tumor (also termed Fibroid or Leiomyoma) (ICD-10-CM D39.10), Cancer, Oncology & Supportive Care protocols prioritize immunohistochemistry [Granulosa cell tumor D39.10] paired with baseline and interval Pathology / Molecular in Granulosa cell tumor (D39.10: Genomic Staging) assessment.
- 2 Real-world patient consensus: Synonyms for Granulosa cell tumor (D39.10): Fibroid, Leiomyoma, Fibrous (Cancer & Oncology).
- 3 Typical cash cost range: Primary evaluation for Granulosa cell tumor incorporates immunohistochemistry [Granulosa cell tumor D39.10] and symptom diary review.
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Granulosa cell tumor (D39.10): Pathology / Molecular in Granulosa cell tumor (D39.10: Genomic Staging) & Complete Blood Count in Granulosa cell tumor (D39.10: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (D39.10)).
Ask our AI Specialists anything about Granulosa cell tumor
What Is Granulosa cell tumor?
For patients presenting with Granulosa cell tumor (also termed Fibroid or Leiomyoma) (ICD-10-CM D39.10), Cancer, Oncology & Supportive Care protocols prioritize immunohistochemistry [Granulosa cell tumor D39.10] paired with baseline and interval Pathology / Molecular in Granulosa cell tumor (D39.10: Genomic Staging) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Granulosa cell tumor (D39.10, Cancer & Oncology) reflects angiogenesis [Granulosa cell tumor D39.10]. longitudinal control is benchmarked via Pathology / Molecular in Granulosa cell tumor (D39.10: Genomic Staging).
Common Symptoms & Clinical Signs
- • Presentation of Granulosa cell tumor (D39.10): abnormality detected early in Granulosa cell tumor (D39.10: on age-appropriate screening)
- • Secondary Granulosa cell tumor clinical sign: persistent painless lump, in Granulosa cell tumor (D39.10: non-healing ulcer/mole change,)
- • Symptom flares in Granulosa cell tumor correlating with Pathology / Molecular in Granulosa cell tumor (D39.10: Genomic Staging) deviation outside Guideline-concordant surveillance (D39.10)
- • Functional cancer & oncology impact requiring immunohistochemistry [Granulosa cell tumor D39.10] evaluation (D39.10)
Granulosa cell tumor Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D39.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Pathology / Molecular in Granulosa cell tumor (D39.10: Genomic Staging) | Guideline-concordant surveillance (D39.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Granulosa cell tumor (D39.10: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (D39.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Granulosa cell tumor (D39.10: Organ Function Panel) | Preserved renal/hepatic clearance (D39.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Granulosa cell tumor
Treatment selection for Granulosa cell tumor depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Granulosa cell tumor)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Body-mass index on treatment and outcome in locally advanced rectal cancer: A: What a 1,236-Participant Study Found In our study, underweight and overweight correlated with inferior DFS, underweight experienced more organ toxicity and obesity was associated with an increased risk of abdominoperineal resection and poorer overall. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2021-11-15 • Phase III Randomized Trial | N = 1,236 | 90/100 | PMID 34619239 ↗ |
| Can This Approach Help? Inside the Latest Research on Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance Despite meeting their primary endpoints (PFS), neither final OS analysis of TOURMALINE-MM3/-MM4 showed statistically significant differences between fixed-duration ixazomib maintenance. Blood cancer journal • 2025-12-04 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41345095 ↗ |
| Can This Approach Help? Inside the Latest Research on Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Enzalutamide significantly reduced risk of PSA progression, improved secondary efficacy endpoints, and was well tolerated in chemotherapy-naïve Asian patients with mCRPC with disease progression despite ADT. Advances in therapy • 2022-06-15 • Phase III Randomized Trial | N = 198 | 88/100 | PMID 35397772 ↗ |
| New Insights on Phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as: What a 254-Participant Study Found Of grade 3 or 4 side effects, a significantly higher incidence of neuropathy in AP and thrombocytopenia in GP is noted. Nature communications • 2022-07-12 • Phase III Randomized Trial | N = 254 | 87/100 | PMID 35821019 ↗ |
| Can This Approach Help? Inside the Latest Research on Short-term outcomes of chemoradiotherapy and local excision versus total CRT-TEM treatment obtains high pathological complete response rates (44.3%) and a high CRT compliance rate (98.8%). Annals of oncology : official journal of the European Society for Medical Oncology • 2023-01-15 • Phase III Randomized Trial | N = 81 | 82/100 | PMID 36220461 ↗ |
Granulosa cell tumor Patient Community & “People Like Me” Threads
Filter Granulosa cell tumor community threads and patient logs by age, biological sex, dosage, and treatment duration.